Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2019 01:15 ET | Source: Novartis Pharma AG

Novartis highlights new publication showing IL-17A antibody Cosentyx® improves inflammation and rapidly suppresses IL-23 in plaque psoriasis

New data show that Cosentyx modulates gene expression leading to substantial improvement of inflammation, as early as Week 12 by reversing plaque histopathology in the majority of patients[1] ...
June 24, 2019 16:20 ET | Source: Novartis Pharma AG

Novartis provides update on phase 2b ENCORE-LF trial in NASH cirrhosis

Conatus today announced top-line results from the ENCORE-LF trial, which did not meet its primary endpoint Novartis remains fully committed to pursuing the development of multiple compounds in...
June 24, 2019 01:15 ET | Source: Novartis Pharma AG

Silvia Schweickart wird Vorsitzende der Geschäftsleitung der Novartis Pharma Schweiz AG in Rotkreuz

Rotkreuz, 24. Juni, 2019 - Silvia Schweickart übernimmt zum 1. Juli 2019 den Vorsitz der Geschäftsleitung der Novartis Pharma Schweiz AG und wird als Site Head auch für den gesamten Standort...
June 14, 2019 02:30 ET | Source: Novartis Pharma AG

Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001)

Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for...
June 12, 2019 01:20 ET | Source: Novartis Pharma AG

Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show

Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg[1] Data at 2 years demonstrate over 50% of adults with active...
June 12, 2019 01:15 ET | Source: Novartis Pharma AG

Novartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis

First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people...
June 07, 2019 01:00 ET | Source: Novartis Pharma AG

Novartis stellt neue Leiterin der Pharmaceuticals Business Unit vor

Marie-France Tschudin, erfahrene Novartis Führungsperson, zur Präsidentin von Novartis Pharmaceuticals ernannt Basel, 7. Juni 2019 - Novartis kündigte heute an, dass Marie-France Tschudin, derzeit...
June 07, 2019 01:00 ET | Source: Novartis Pharma AG

Novartis announces new leader of Pharmaceuticals Business Unit

Marie-France Tschudin, an experienced Novartis leader, appointed to President, Novartis Pharmaceuticals Basel, June 7, 2019 - Novartis announced today that Marie-France Tschudin, currently...
June 06, 2019 01:15 ET | Source: Novartis Pharma AG

Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible

Data show 60% of iscalimab-treated transplant patients have normal kidney histology at least 1 year after transplant vs 0% with tacrolimus (current standard of care)[1] Less than half of donated...
June 04, 2019 13:00 ET | Source: Novartis Pharma AG

Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®

Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine ...